← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $624B	2,755	-10	-0.4%	$253B
2	2 Pfizer PFE $169B	2,377	-14	-0.6%	$176B
3	3 Merck MRK $372B	2,299	+6	+0.3%	$164B
4	4 AbbVie ABBV $510B	2,020	-14	-0.7%	$76.4B
5	5 Amgen AMGN $238B	1,865	-22	-1%	$86B
6	6 Bristol-Myers Squibb BMY $125B	1,777	-37	-2%	$60.6B
7	7 Gilead Sciences GILD $197B	1,484	-9	-0.6%	$70.6B
8	8 Novartis NVS $288B	1,094	-40	-4%	$23.5B
9	9 GSK GSK $99.2B	804	-44	-5%	$11.2B
10	10 Regeneron Pharmaceuticals REGN $83.1B	658	-61	-8%	$23.1B
11	11 AstraZeneca AZN $261B	547	-15	-3%	$19B
12	12 Incyte INCY $23.1B	511	-8	-2%	$17B
13	13 DELISTED Exact Sciences EXAS	472	+48	+11%	$13.5B
14	14 Jazz Pharmaceuticals JAZZ $14B	416	-11	-3%	$7.19B
15	15 Takeda Pharmaceutical TAK $63.2B	347	-43	-11%	$2.57B
16	16 Exelixis EXEL $15.6B	346	-32	-8%	$5.08B
17	SGEN 17 DELISTED Seagen Inc. Common Stock SGEN	324	-24	-7%	$11.1B
18	18 Qiagen QGEN $9.54B	262	0	0%	$5.79B
19	19 NeoGenomics NEO $2.2B	253	+18	+8%	$1.93B
20	20 Myriad Genetics MYGN $415M	235	-27	-10%	$2.14B
21	21 DELISTED Blueprint Medicines BPMC	220	+17	+8%	$4.68B
22	22 Guardant Health GH $22.3B	217	+67	+45%	$6.57B
23	23 BeOne Medicines Ltd ONC $42B	203	+4	+2%	$6.09B
24	24 Halozyme HALO $13.8B	202	+1	+0.5%	$2.1B
25	25 Opko Health OPK $1.19B	200	-1	-0.5%	$377M